To those who say “impossible, impractical, unrealistic,” we say adsa:
We are developing an innovative new class of medicines called RNAi therapeutics that we believe have the potential to transform the lives of people living with rare diseases.
AT THE FOREFRONT OF CHANGE
Alnylam is leading the translation of RNA interference (RNAi) into an innovative new class of medicines for patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.
Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform and deep pipeline of investigational medicines, including five product candidates that are in late-stage development and three products approved in the U.S and the European Union.